Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesityBoehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment4 days ago